SABS · SAB Biotherapeutics, Inc. · Insider Trading

Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

Includes 38,402 shares of Common Stock and 3,433 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

Includes 37,158 shares of Common Stock and 5,150 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

Includes 34,553 shares of Common Stock and 8,743 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").

Includes 31,946 shares of Common Stock and 12,338 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), of SAB Biotherapeutics, Inc. (the "Issuer"), held by Sessa Capital (Master), L.P. (the "Fund") into common stock, par value $0.0001 per share (the "Common Stock") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock.

The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion.

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), of SAB Biotherapeutics, Inc. (the "Issuer"), held by Sessa Capital (Master), L.P. (the "Fund") into common stock, par value $0.0001 per share (the "Common Stock") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock.

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), of SAB Biotherapeutics, Inc. (the "Issuer"), held by Sessa Capital (Master), L.P. (the "Fund") into common stock, par value $0.0001 per share (the "Common Stock") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock.

The Fund acquired the Preferred Stock of the Issuer for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025. The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties from converting the Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion.

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the automatic conversion of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), of SAB Biotherapeutics, Inc. (the "Issuer"), held by Sessa Capital (Master), L.P. (the "Fund") into common stock, par value $0.0001 per share (the "Common Stock") of the Issuer. The Preferred Stock became automatically convertible on September 29, 2025, the first trading day following the announcement of the approval by the stockholders of the Issuer of the issuance of all Common Stock upon conversion of the Preferred Stock.

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs").

Includes 29,340 shares of Common Stock and 15,932 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the "Data Release Warrants") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Release Date (as defined in the Data Release Warrant).

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the "Enrollment Warrants") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Fund in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant).

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $175 per share (the "Enrollment Warrants") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Enrollment Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Enrollment Date (as defined in the Enrollment Warrant).

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the acquisition by Sessa Capital (Master), L.P. (the "Fund") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of SAB Biotherapeutics, Inc. (the "Issuer") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the "SPA"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the "Stockholder Approval"), subject to the Beneficial Ownership Limitation (as defined below).

The Preferred Stock is subject to a beneficial ownership limitation that prevents the Sessa Parties (as defined below) from converting the Series B Preferred Stock into Common Stock to the extent that such conversion would result in the Sessa Parties beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion (the "Beneficial Ownership Limitation").

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC (collectively, the "Sessa Parties"). Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the foregoing persons disclaims beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the acquisition by Sessa Capital (Master), L.P. (the "Fund") of shares of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") of SAB Biotherapeutics, Inc. (the "Issuer") for an aggregate purchase price of $39,987,500 pursuant to that certain Securities Purchase Agreement, dated July 21, 2025 (the "SPA"). The Preferred Stock will automatically convert into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") at a conversion price of $1.75 per share upon the receipt by the Issuer of approval by its stockholders of the issuance of all Common Stock issuable upon conversion of the Series B Preferred Stock at a special meeting of stockholders to be held in accordance with the terms of the SPA (the "Stockholder Approval"), subject to the Beneficial Ownership Limitation (as defined below).

The Preferred Stock is subject to a beneficial ownership limitation that prevents the Reporting Persons from converting the Series B Preferred Stock into Common Stock to the extent that such conversion would result in the Reporting Person beneficially owning more than 4.99% of the Issuer's Common Stock outstanding immediately following such conversion (the "Beneficial Ownership Limitation").

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Reflects the acquisition by the Fund of warrants to purchase shares of Preferred Stock at an exercise price of $218.75 per share (the "Data Release Warrants") that accompanied the Preferred Stock purchased pursuant to the SPA. Each Data Release Warrant is exercisable until the earlier of (x) July 21, 2030 and (y) the 30th trading day after the Issuer notifies the Reporting Person in writing of the Phase II Release Date (as defined in the Data Release Warrant).

These securities of the Issuer are beneficially owned by (i) the Fund, directly, (ii) Sessa Capital GP, LLC, indirectly as a result of being the sole general partner of the Fund, (iii) Sessa Capital IM, L.P., indirectly as a result of being the investment adviser for the Fund, (iv) Sessa Capital IM GP, LLC, indirectly as a result of being the sole general partner of Sessa Capital IM, L.P., and (v) John Petry, indirectly as a result of being the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC. Andrew Moin, an Analyst and Partner with the Fund, is a member of the board of directors of the Issuer. Each of the Reporting Persons and Mr. Moin disclaim beneficial ownership of any securities reported by any person except to the extent of their pecuniary interest therein.

Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs").

Includes 24,128 shares of Common Stock and 23,121 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents shares of the Issuer's common stock ("Common Stock") withheld to satisfy tax withholding requirements on the vesting of the Issuer's restricted stock units ("RSUs").

Includes 21,712 shares of Common Stock and 26,716 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.

Each RSU represents a contingent right to receive one share of Common Stock.

Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on November 1, 2025, 2026, and 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on November 1, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan, as amended.

The shares underlying the option vest over a four-year period, with 1/4 vesting on the one-year anniversary date from the Reporting Person's commencement of service as Chief Financial Officer (August 12, 2025), and the remainder vesting thereafter in equal monthly installments over a three year period.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on May 3, 2025, 2026, and 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.